Article
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2018
Abad A, Martínez-Balibrea E, Viéitez J M, Alonso-Orduña V, García Alfonso P, Manzano J L, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E
Abstract excerpt
Background: There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.